

02-10-00

Box Seg.

02/09/00
1c571 U.S. PTO

EXPRESS MAIL CERTIFICATE

Date 2/9/2000 Label No. E4503340112

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail" Office to Addressee" service.

D B Peck [Signature]
Name (Print) Signature

1c551 U.S. PTO
09/501171
02/09/00

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

DARBY & DARBY P.C.

805 Third Avenue
New York, New York 10022
212-527-7700

Docket No: 1034/1F811US1

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

Enclosed please find an application for United States patent as identified below:

Inventor/s (name ALL inventors): Peter ST. GEORGE-HYSLOP; and
Paul E. FRASER

Title: PROTEINS RELATED TO NEURONAL REGENERATION AND USES THEREOF

including the items indicated:

1. Specification and 13 claims: 4 indep.; 9 dep.; 0 multiple dep.
2. ☐ Executed declaration and power of attorney
☒ Unexecuted declaration and power of attorney
3. ☐ Formal drawings, sheets (Figs.)
☐ Informal drawings, sheets (Figs.)

4. ☐ Assignment for recording to:
5. ☐ Verified Statement Claiming Small Entity Status
6. ☐ Check in amount of \$.00, (\$ filing; \$ recording; \$ surcharge)
(See attached **Fee Computation Sheet**)
7. ☐ Preliminary Amendment.
8. ☒ Please amend the description by inserting the following paragraph after the line containing the title on page 1:
"This patent application claims the priority of U.S. provisional patent application No. 60/119,835, which is incorporated herein by reference."
9. Sequence Listing. The paper (13 pp.) and electronic copies of the sequence listing are identical.

Respectfully submitted,



Paul F. Fehlner, Esq.

Reg. No. 35,135

Attorney for Applicant(s)

PATENT FEE COMPUTATION SHEET

	No. of Claims Presented	Extra Claims Previously Paid For	Number of Extra Claims	Rate
Basic Fee				\$690.00
Total Claims	13 - 20	- 0 = 0	x \$18.00	\$0.00
Independent Claims	4 - 3	- 0 = 1	x \$78.00	\$78.00
Multiple Dependent Claims		0 - if so, add	\$260.00	\$0.00
Surcharge for late submission of filing fee and/or declaration (\$130.00)				\$0.00
SUBTOTAL				\$768.00
[] Small Entity REDUCTION (Half of Subtotal)				\$0.00
Fee for recordation of assignment (\$40.00)				\$0.00
Charge for filing non-English language application (\$130.00)				\$0.00
TOTAL				\$768.00

EXPRESS MAIL CERTIFICATE

Date 2/9/2000 Label No. 92503340112

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

Name (Print)

Signature

1034/1F811-US1

**PROTEINS RELATED TO NEURONAL REGENERATION
AND USES THEREOF**

FIELD OF THE INVENTION

The present invention relates generally to the treatment of neurological injury and dysfunction associated with central nervous system trauma. In particular, the invention is directed to the identification of proteins which induce neuronal regeneration.

BACKGROUND OF THE INVENTION

The peripheral nervous system (PNS) comprises highly organized groups of axon fibers or nerves external to the brain and spinal cord, such as the nerves in the limbs. In response to nerve damage, the peripheral nervous system often attempts to repair itself. While the return of lost functions is usually incomplete, generally the injured organism can adapt and function.

By contrast, damage to the central nervous system (CNS), comprising the brain and spinal cord, is generally more serious, usually causing permanent severe disability or even death.

A number of conditions are known to affect both growth and spontaneous regeneration in nerves, but the underlying mechanisms are not well understood (Gibson *et al.*, In *Compend. Contin. Educ. Pract. Vet.*, vol. 11, pp., 1989, 938-945; and Danilooff *et al.*, J. Cell Bio., 1986, 103:929-945). These conditions include the location of injury, the type of injury, the severity of injury, and the age and general health of the patient.

It has been reported that minor prior recoveries somehow prime the nerve for greater recovery in secondary lesions, for example, recovery from an earlier compression injury.

There are no previous reports of an effective treatment for injuries to neurons of the central nervous system, *i.e.*, the brain and spinal cord (*see*, M. Walker, New Engl. J. Med., 1991, 324:1885-1887.

The lack of effective treatments for nervous system injuries may be due to an insufficient understanding both of the formation of the nervous system and of its responses to injuries. Several attempts have been made to electrically stimulate injured nerves to try to cause regrowth; recovery was highly variable and inadequate (*see*, B. Siskin *et al.*, Restorative Neurology and Neuroscience, 1990, 1:303-309; *see* generally J. Danilooff *et al.*, "The Molecular Bases of Nerve Regeneration," in S. Malhotra (ed.), Advances in Neural Science, vol. 2, 1993). The method that is currently used most often to close gaps in severed nerves uses grafts of the patient's own sensory nerves, typically taken from the ankle; a minimal degree of recovery and permanent analgesia of the donor foot are the usual results.

Because an injured spinal cord has very limited ability to recover spontaneously, and because the consequences of spinal cord injuries can be so serious, there is a particular need for an effective treatment of spinal cord injuries. Paralytic spinal cord injuries in the United States alone occur at the rate of about 10,000 per year. Although the mortality rate is less than 10%, approximately 720 Americans per million population are permanently disabled as a result of spinal cord injuries. Most of the injured are young people in the most productive stage of life.

Following injury to neuronal cells in the central nervous system, there is often an abortive attempt by injured neural cells to generate new cellular extensions (dendrites and axons) in order to reestablish inter-neural contacts. In the central nervous system, these nerve sprouting and regeneration activities are often modest and only poorly sustained such that regeneration following stroke, trauma, spinal cord injury, etc., does not usually occur.

Thus, there is a need in the art for material and methods for treating neuronal injury.

SUMMARY OF THE INVENTION

The present invention addresses this need. Applicants have surprisingly discovered that a neuron-specific armadillo protein -- Neural Plakophilin Related Armadillo Protein (NPRAP) -- causes the development of numerous long, cellular extensions, which are similar to axonal sprouting observed during neuronal regeneration and synapse formation.

One aspect of the invention is directed to a method of stimulating growth of nerve cells, which method comprises contacting the nerve cells with an hNPRAP having nerve growth stimulating activity in an amount effective to cause nerve cell growth.

In a specific embodiment related to a method of stimulating growth of nerve cells, the method comprises contacting nerve cells with an hNPRAP stimulating agent in an amount sufficient to induce the expression of an hNPRAP and cause nerve cell growth.

A further related aspect of the invention is directed to a method of stimulating neuronal regeneration in a mammal, which method comprises administering to the mammal in need thereof an effective amount of an hNPRAP or an effective amount of an hNPRAP expression stimulating agent as set forth above.

A further aspect of the invention is related to a pharmaceutical composition comprising an hNPRAP having nerve growth stimulating activity, and a pharmaceutically acceptable carrier.

Yet another aspect of the invention is related to a pharmaceutical composition comprising an hNPRAP expression stimulating agent and a pharmaceutically acceptable carrier.

In a specific embodiment, the invention provides a pharmaceutical composition comprising an hNPRAP gene therapy vector, which vector comprises a polynucleotide encoding hNPRAP and a promoter for expressing hNPRAP, and a carrier. Naturally, such gene therapy vectors are also part of the invention as well.

A further aspect of the invention relates to a method for identifying substances that modulate the expression of hNPRAP, which method comprises contacting cultured cells that express hNPRAP with a test substance measuring levels of hNPRAP, as compared to a control in

which the same cells that express hNPRAP are not contacted with the test substance, as an indication of modulatory activity of said test substance.

These and other aspects of the invention are disclosed more fully in the accompanying detailed description.

5

DETAILED DESCRIPTION

The human Neural Plakophilin Related Armadillo Protein ("hNPRAP") (also described as GT24) consensus cDNA (SEQ ID NO:3) encodes a protein (SEQ ID NO:4) of 1084 amino acid residues with a unique N-terminus, but with homology to proteins with armadillo (arm) repeat motifs at its C-terminus.

10

Applicants have now discovered that over-expression of hNPRAP, or functional derivatives thereof containing one or more armadillo repeats, causes the development of numerous long, dendritic processes which typically terminate upon distantly located cells. These target cells need not necessarily be expressing hNPRAP. The hNPRAP induced cellular extensions are highly similar to the axonal sprouting seen during neuronal regeneration and synapse formation.

15

Nucleotides 2920-2997 of the hNPRAP cDNA overlap the anonymous microsatellite locus D5S478, therefore placing the hNPRAP gene on chromosome 5p15 near the Cri-du-Chat deletion locus, a syndrome associated with congenital malformation and gross mental retardation. hNPRAP is described in detail in copending commonly assigned U.S. Application Serial Nos. 08/888,077, filed July 3, 1997 (PCT/CA97/00051), and 09/227,725, filed January 8, 1999 (PCT/CA99/00018), both of which are incorporated herein by reference.

20

As described in U.S. Application Serial Nos. 08/888,077 (PCT/CA97/00051) and 09/227,725 (PCT/CA99/00018), hNPRAP is known to interact with Presenilin I ("PS1") and Presenilin II ("PS2") by direct protein:protein interaction studies. The domain of the PS1 protein that interacts with hNPRAP has also been shown to interact with other proteins, such as armadillo repeat proteins p0071 and β -catenin.

25

On Northern blots, the hNPRAP gene is expressed as a range of transcripts of 3.9 to 5.0 kb in several regions of adult human brain, but is expressed at only very low levels in most non-neurologic tissues. Studies have shown that PS1 and hNPRAP are both expressed in the same cell types and in adjacent/contiguous subcellular compartments.

5 *In situ* hybridization studies indicate that the transcriptional pattern of PS1 and NPRAP overlap both in the brain of 4 month old mice, and in the neural tube and dorsal root ganglia of murine embryos. Both genes are expressed at high levels in dentate and hippocampal neurons, in scattered neocortical neurons, and in cerebellar Purkinje cells in adult mouse brain (Lee *et al.*, J. Neurosci., 1996, 16:7513-7525; Paffenholz and Franke, Differentiation, 1997, 10 61:293-304). Immunocytochemical studies show that PS1 and hNPRAP have overlapping intracellular distributions. Thus, in non-confluent transfected cell cultures, hNPRAP has a predominantly perinuclear cytoplasmic distribution contiguous with that of PS1. In contrast, in confluent cells with abundant cell:cell contacts, hNPRAP is predominantly located near the cell membrane close to inter-cellular contact zones while PS1 retains its predominantly perinuclear distribution.

15 The invention is directed to the use of an hNPRAP to stimulate neuronal regeneration and axon sprouting following a wide variety of insults and injuries. An "hNPRAP" is defined herein as a biologically active polypeptide that contains a sequence of hNPRAP that mediate its nerve cell growth stimulating activity, *e.g.*, the *armadillo* repeats. Thus, hNPRAP includes full-length (naturally occurring) hNPRAP, as well as biologically active analogues thereof. By "analogues" it is meant modifications such as point mutations, amino acid substitutions, additions or deletions, or other mammalian homologues, such as mouse (SEQ ID NO:5 and SEQ ID NO:6), which have similar activity to hNPRAP, the identification and selection of which are well-known to those skilled in the art. In addition to hNPRAP, the use of 20 recombinant proteins such as p120cas and chimeric proteins having all or parts of the C-terminal armadillo-like repeat and C-terminal unique sequences of hNPRAP may also be utilized in the practice of this invention. Analogues of these proteins which replicate the effects thereof may also be utilized in the practice of this invention.

In a first embodiment, the invention provides a method of stimulating growth of nerve cells, comprising contacting nerve cells with an hNPRAP.

A second embodiment is directed to a method of stimulating growth of nerve cells, comprising contacting nerve cells with an hNPRAP stimulating agent in an amount sufficient to induce the expression of hNPRAP. Such agents may induce the expression of hNPRAP by positively binding to the hNPRAP gene to induce expression, or may alter the interaction of hNPRAP with an inhibitor of hNPRAP expression, *e.g.*, by binding to the inhibitor itself or to hNPRAP such that the inhibitor no longer modulates the expression of hNPRAP.

Alternatively, the expression of hNPRAP may be induced by the use of an appropriate viral vector system, or by the administration of recombinant proteins, biological molecules or small molecules which simulate or resemble either the *armadillo* binding domain of the presenilins or the *armadillo* repeats of hNPRAP. Another embodiment is directed to a method for identifying substances that simulate or resemble (mimic) either the *armadillo* binding domain of the presenilins or the *armadillo* repeats of hNPRAP, and which substances cause neural growth. Candidate compounds which are shown to mimic either the *armadillo* binding domain of the presenilins or the *armadillo* repeats of hNPRAP may be produced in pharmaceutically useful quantities for use in the treatment of neurological injury and dysfunction associated with central nervous system trauma. Candidate compounds include endogenous cellular components which interact with the presenilins *in vivo* and which, therefore, provide new targets for pharmaceutical and therapeutic interventions, as well as recombinant, synthetic and otherwise exogenous compounds which may have presenilin binding capacity and, therefore, may be candidates for pharmaceutical agents. Thus, in one procedure, cell lysates or tissue homogenates (*e.g.*, human brain homogenates, lymphocyte lysates) may be screened for proteins or other compounds which bind to one of the normal or mutant presenilins. Alternatively, any of a variety of exogenous compounds, both naturally occurring and/or synthetic (*e.g.*, libraries of small molecules or peptides), may be screened for presenilin binding capacity. In each of these embodiments, an assay is conducted to detect binding between a presenilin component containing at least the interacting domain of a presenilin protein described herein and some other moiety.

As described in U.S. Application Serial No. 09/227,725, the presenilin domain that interacts with PS-interacting proteins, such as armadillo repeat proteins hNPRAP, p0071 and β -catenin, has been identified as including or being contained in the sequence of amino acid residues from about 260 to about 409 of PS1 or corresponding residues from about 260 to about 390 in PS2. More preferably, the interacting domain contains or is contained in amino acid residues from about 372 to about 399 of PS1 or corresponding residues from about 350 to about 380 in PS2. The amino acid sequences of wild-type human PS1 and PS2 are shown in SEQ ID NO:1 and SEQ ID NO:2, respectively.

Binding may be detected by indirect functional measures reflecting the functional consequences of the interaction (*e.g.*, changes in intracellular Ca^{2+} , Na^{+} , K^{+} , or GTP/GDP ratio, changes in apoptosis or microtubule associated protein phosphorylation, changes in $\text{A}\beta$ peptide production or changes in the expression of other downstream genes which can be monitored by differential display, 2D gel electrophoresis, differential hybridization, or SAGE methods) or by direct measures such as immunoprecipitation, the Biomolecular Interaction Assay (BIAcore) or alteration of protein gel electrophoresis. The preferred methods involve variations on the following techniques: (1) direct extraction by affinity chromatography; (2) co-isolation of presenilin components and bound proteins or other compounds by immunoprecipitation; (3) BIAcore analysis; and (4) the yeast two-hybrid systems. Other procedures include methods which detect abnormal processing of PS1, PS2, APP, or proteins reacting with PS1, PS2, or APP (*e.g.*, abnormal phosphorylation, glycosylation, glycation amidation or proteolytic cleavage) alterations in presenilin transcription, translation, and post-translational modification; alterations in the intracellular and extracellular trafficking of presenilin gene products; or abnormal intracellular localization of the presenilins.

The proteins or other compounds identified by these methods may then be assayed for their ability to promote sprouting in axons of neuronal cultures or dendrite formation in non-neurological cells using morphometric analyses which are well-known to those skilled in the art of neuronal regeneration. Alternatively, assays for regeneration following sectioning of the optic

nerve, spinal cord, etc. in animals may be performed. Such assays are well-known to those in the field of neuronal regeneration.

The proteins or other compounds identified by these methods may be purified and characterized by any of the standard methods known in the art. Proteins may, for example, be purified and separated using electrophoretic (*e.g.*, SDS-PAGE, 2D PAGE) or chromatographic (*e.g.*, HPLC) techniques and may then be microsequenced. For proteins with a blocked N-terminus, cleavage (*e.g.*, by CNBr and/or trypsin) of the particular binding protein is used to release peptide fragments. Further purification/characterization by HPLC and microsequencing and/or mass spectrometry by conventional methods provides internal sequence data on such blocked proteins. For non-protein compounds, standard organic chemical analysis techniques (*e.g.*, IR, NMR and mass spectrometry; functional group analysis; X-ray crystallography) may be employed to determine their structure and identity.

These hNPRAPs, and compounds which activate hNPRAP, may be employed in combination with a suitable pharmaceutical, physiologically acceptable carrier. Administration of hNPRAP of this invention can be through the administration of hNPRAP peptides agonists or antagonists synthesized from recombinant constructs of hNPRAP DNA or from peptide chemical synthesis (Woo, *et al.*, Protein Engineering, 1989, 3:29-37) or in the form of gene therapy (Goldspiel *et al.*, Clin. Pharm., 1993, 12:488; Wu and Wu, Biotherapy, 1991, 3:87; Mulligan, Science, 1993, 260:926; Morgan and Anderson, Ann. Rev. Biochem., 1993, 62:191; and, May TIBTECH, 1993, 11:155).

Generally, hNPRPA and/or activating agent(s) are administered as pharmaceutical compositions comprising an effective amount of hNPRAP and/or activating agent(s) in a pharmaceutical carrier. These reagents can be combined for therapeutic use with additional active or inert ingredients, *e.g.*, in conventional pharmaceutically acceptable carriers or diluents, *e.g.*, immunogenic adjuvants, along with physiologically innocuous stabilizers and excipients. A pharmaceutical carrier can be any compatible, non-toxic substance suitable for delivering the compositions of the invention to a patient.

The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Animal testing of effective doses for treatment of particular injuries will provide further predicative indication of human dosage. Various considerations are described, *e.g.*, in Gilman *et al.* (eds.) (1990) Goodman and Gilman's; The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, PA. Methods for administration are discussed therein and below, *e.g.*, for intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others. Pharmaceutically acceptable carriers include water, saline, buffers and other compounds described, *e.g.*, in the Merck Index, Merck & Co., Rahway, New Jersey, and in Remington, *supra*. Slow release formulations, or a slow release apparatus, may be used for continuous administration.

Dosage ranges for hNPRAP and/or activating agent(s) would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10 μ M concentrations, usually less than about 100 nM, preferably less than about 10 pM (picomolar), and most preferably less than about 1 fM (femtomolar), with an appropriate carrier. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstance is reached. Determination of the proper dosage and administration regime for a particular situation is within the skill of the art.

Polypeptides and other compounds of the present invention which activate or inhibit hNPRAP may be employed alone or in conjunction with other compounds, such as therapeutic compounds. Once identified by the methods described above, the candidate compounds may then be produced in quantities sufficient for pharmaceutical administration or testing (*e.g.*, mg or mg or greater quantities), and formulated in a pharmaceutically acceptable carrier (*see, e.g., Remington's, supra*).

Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

The compositions of the present invention may be administered orally, parenterally, by spray inhalation, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.

Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers

include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

The methods and compositions of this invention may be used to treat nerve damage caused by a wide variety of diseases or physical traumas. These include, but are not limited to, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, stroke and ischemia associated with stroke, neural paropathy, other neural degenerative diseases, motor neuron diseases, sciatic crush, peripheral neuropathy, particularly neuropathy associated with diabetes, spinal cord injuries and facial nerve crush.

The hNPRAP polynucleotides, polypeptides, agonists and antagonists that are polypeptides may be employed in accordance with the present invention by expression of such polypeptides in treatment modalities often referred to as "gene therapy". Thus, for example, cells from a patient may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex vivo*. The engineered cells can then be provided to a patient to be treated with the polypeptide. In this embodiment, cells may be engineered *ex vivo*, for example, by the use of a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention. Such methods are well-known in the art and their use in the present invention will be apparent from the teachings herein.

Similarly, cells may be engineered *in vivo* for expression of a polypeptide *in vivo* by procedures known in the art. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral or viral vector, as discussed above. The retroviral expression construct may then be isolated. A packaging cell is transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention, such that the packaging cell now produces infectious viral particles containing the gene of interest. These viral particles may be administered to a patient for engineering cells *in vivo* and expression of the polypeptide *in vivo*. These and other methods for administering a polypeptide of the present invention should be apparent to those skilled in the art from the teachings of the present invention.

Retroviruses or viruses from which the plasmid vectors hereinabove-mentioned may be derived include, but are not limited to, SimiForest Virus, Lenti-virus, Moloney Murine Leukemia Virus, Spleen Necrosis Virus, Rous Sarcoma Virus, Harvey Sarcoma Virus, Avian Leukosis Virus, Gibbon Ape Leukemia Virus, Human Immunodeficiency Virus, Adenovirus, Myeloproliferative Sarcoma Virus, and Mammary Tumor Virus. In a preferred embodiment, the retroviral plasmid vector is derived from Moloney Murine Leukemia Virus.

Such vectors will include one or more promoters for expressing the polypeptide. Suitable promoters which may be employed include, but are not limited to, the retroviral LTR; the SV40 promoter; and the human cytomegalovirus (CMV) promoter described in Miller *et al.*, Biotechniques, 1989, 7:980-990. Cellular promoters such as eukaryotic cellular promoters including, but not limited to, the histone, RNA polymerase III, and β -actin promoters, can also be used. Additional viral promoters which may be employed include, but are not limited to, adenovirus promoters such as the adenoviral major late promoter, thymidine kinase (TK) promoters such as the Herpes Simplex thymidine kinase promoters; the respiratory syncytial virus (RSV) promoters; and B19 parvovirus promoters. The selection of a suitable promoter will be apparent to those skilled in the art from the teachings contained herein.

The nucleic acid sequence encoding the polypeptide of the present invention may be placed under the control of an inducible promoter. Suitable inducible promoters which may be

employed include, but are not limited to, the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters; and human growth hormone promoters. The promoter may also be the native promoter which controls the gene encoding the polypeptide.

5 The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, .PSI.-2, .omega.-AM, PA12, T19-14X, VT-19-17-H2, .omega.CRE, .omega.CRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, A., Human Gene Therapy, 1990, 1:5-14. The vector may be transduced into the packaging cells
10 through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host. The producer cell line will generate infectious retroviral vector particles, which include the nucleic acid sequence(s) encoding the polypeptides. Such retroviral vector particles may then be
15 employed to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express the nucleic acid sequence(s) encoding the polypeptide. Eukaryotic cells which may be transduced include, but are not limited to, embryonic stem cells, embryonic carcinoma cells, as well as hematopoietic stem cells, hepatocytes, fibroblasts, myoblasts, keratinocytes, endothelial cells, and bronchial epithelial cells.

* * *

Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements
25 may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.

Each patent, patent application, publication, and procedure disclosed in this application is specifically incorporated by reference in its entirety.

WHAT IS CLAIMED IS:

1 1. A method of stimulating growth of nerve cells, which method comprises
2 contacting nerve cells with a human Neural Plakophilin Related *Armidillo* Protein (hNPRAP)
3 polypeptide having nerve growth stimulating activity in an amount effective to cause nerve cell
4 growth.

1 2. The method according to claim 1, wherein the hNPRAP is a full length
2 hNPRAP.

1 3. The method according to claim 2, wherein the hNPRAP has an amino acid
2 sequence as set forth in SEQ ID NO:4.

1 4. The method according to claim 1, wherein the growth of nerve cells results
2 in neuronal regeneration.

1 5. The method according to claim 4, wherein the neuronal regeneration results
2 in synapse formation.

1 6. The method according to claim 1, wherein the nerve cells are contacted
2 with an hNPRAP induced by an hNPRAP expression stimulating agent.

1 7. The method according to claim 6, wherein the hNPRAP expression
2 stimulating agent is a gene therapy vector comprising a polynucleotide encoding the hNPRAP and
3 a promoter for expressing the hNPRAP.

1 8. The method according to claim 6, wherein the growth of nerve cells results
2 in neuronal regeneration.

1 9. A pharmaceutical composition comprising an hNPRAP having nerve
2 growth stimulating activity and a carrier.

1 10. The pharmaceutical composition of claim 9, wherein the hNPRAP is a full
2 length hNPRAP.

1 11. The pharmaceutical composition of claim 10, wherein the hNPRAP has an
2 amino acid sequence as set forth in SEQ ID NO:4.

1 12. A pharmaceutical composition comprising an hNPRAP gene therapy
2 vector, which vector comprises a polynucleotide encoding the hNPRAP and a promoter for
3 expressing the hNPRAP, and a carrier.

1 13. A method of identifying substances that modulate the expression of
2 hNPRAP, which method comprises measuring the levels of hNPRAP expressed in cultured cells
3 that express hNPRAP contacted with a test substance as compared to a control, wherein a
4 difference in the level of hNPRAP expression in the cells contacted with the test substance
5 compared to the control indicates that the test substance modulates expression of hNPRAP.

ABSTRACT OF THE INVENTION

The invention provides a method for stimulating nerve growth, which also includes nerve regeneration, by contacting nerve cells with human Neural Plakophilin Related *Armadillo* Protein (hNPRAP). In a specific embodiment, hNPRAP causes the development of numerous long, cellular extensions, which are similar to axonal sprouting observed during neuronal regeneration and synapse formation. The invention further relates to pharmaceutical compositions comprising an hNPRAP, or alternatively a gene therapy vector that expresses an hNPRAP. Also provided are methods for identifying substances that modulate expression of hNPRAP.

**DECLARATION
AND POWER OF ATTORNEY
Original Application**

As a below named inventor, I declare that the information given herein is true, that I believe that I am the original, first and sole inventor if only one name is listed at 1 below, or a joint inventor if plural inventors are named below, of the invention entitled:

PROTEINS RELATED TO NEURONAL REGENERATION AND USES THEREOF

which is described and claimed in:

[X] the attached specification or [] the specification in application
Serial No.

(for declaration not accompanying appl.)

that I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application, that I acknowledge my duty to disclose information of which I am aware which is material to patentability in accordance with 37 CFR §1.56. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I hereby claim the priority benefits under 35 U.S.C. 119 of any application(s) for patent or inventor's certificate listed below. All foreign applications for patent or inventor's certificate on this invention filed by me or my legal representatives or assigns prior to the application(s) of which priority is claimed are also identified below.

PRIOR APPLICATION(S), IF ANY, OF WHICH PRIORITY IS CLAIMED

COUNTRY

APPLICATION NO.

DATE OF FILING

United States

60/119,835

February 12, 1999

**ALL FOREIGN APPLICATIONS, IF ANY, FILED PRIOR
TO THE APPLICATION(S) OF WHICH PRIORITY IS CLAIMED**

COUNTRY APPLICATION NO. DATE OF FILING

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorney(s) and/or agents(s) to prosecute this application and transact all business in the Patent and Trademark office connected therewith: Gordon D. Coplein #19,165, William F. Dudine, Jr. #20,569, Michael J. Sweedler #19,937, S. Peter Ludwig #25,351, Paul Fields #20,298, Harold E. Wurst #22,183, Joseph B. Lerch #26,936, Melvin C. Garner #26,272, Ethan Horwitz #27,646, Beverly B. Goodwin #28,417, Adda C. Gogoris #29,714, Martin E. Goldstein #20,869, Bert J. Lewen #19,407, Henry Sternberg #22,408, Robert A. Green #28,301, Peter C. Schechter #31,662, Robert Schaffer #31,194, Robert C. Sullivan, Jr. #30,499, Ira J. Levy #35,587, Joseph R. Robinson #33,448, Jay P. Lessler #41,151, Paul F. Fehlner, #35,135

all of the firm of DARBY & DARBY P.C., 805 Third Avenue, New York, NY 10022

SEND CORRESPONDENCE TO:

DIRECT TELEPHONE CALLS TO:

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022

Paul F. Fehlner, Ph.D.

212-527-7700

FULL NAME AND RESIDENCE OF INVENTOR 1

LAST NAME: ST. GEORGE-HYSLOP

FIRST NAME: Peter

MIDDLE NAME:

CITY: Toronto, Ontario

STATE OR FOREIGN COUNTRY: CANADA

COUNTRY OF CITIZENSHIP: Canada

POST OFFICE ADDRESS: 26 Burton Road

CITY: Toronto, Ontario

STATE OR COUNTRY: Canada ZIP CODE: M5P 1T9

FULL NAME AND RESIDENCE OF INVENTOR 2

LAST NAME: FRASER

FIRST NAME: Paul

MIDDLE NAME: E.

CITY: Toronto, Ontario

STATE OR FOREIGN COUNTRY: CANADA

COUNTRY OF CITIZENSHIP: Canada

POST OFFICE ADDRESS: 611 Windermere Avenue CITY: Toronto, Ontario STATE OR COUNTRY: Canada ZIP CODE: M6S 3L9

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR : _____
Peter St. GEORGE-HYSLOP

DATED: _____

SIGNATURE OF INVENTOR : _____
Paul E. FRASER

DATED: _____

(D&D Forms/PTO-21)

SEQUENCE LISTING

<110> St. George-Hyslop, Peter H.
Fraser, Paul E.

<120> Proteins Related to Neuronal
Regeneration and Uses Thereof

<130> 1034/1F811

<160> 6

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 467

<212> PRT

<213> human

<400> 1

Met	Thr	Glu	Leu	Pro	Ala	Pro	Leu	Ser	Tyr	Phe	Gln	Asn	Ala	Gln	Met
1			5					10						15	
Ser	Glu	Asp	Asn	His	Leu	Ser	Asn	Thr	Val	Arg	Ser	Gln	Asn	Asp	Asn
			20				25						30		
Arg	Glu	Arg	Gln	Glu	His	Asn	Asp	Arg	Arg	Ser	Leu	Gly	His	Pro	Glu
			35				40					45			
Pro	Leu	Ser	Asn	Gly	Arg	Pro	Gln	Gly	Asn	Ser	Arg	Gln	Val	Val	Glu
	50					55					60				
Gln	Asp	Glu	Glu	Glu	Asp	Glu	Glu	Leu	Thr	Leu	Lys	Tyr	Gly	Ala	Lys
65					70					75					80
His	Val	Ile	Met	Leu	Phe	Val	Pro	Val	Thr	Leu	Cys	Met	Val	Val	Val
			85						90					95	
Val	Ala	Thr	Ile	Lys	Ser	Val	Ser	Phe	Tyr	Thr	Arg	Lys	Asp	Gly	Gln
			100					105					110		
Leu	Ile	Tyr	Thr	Pro	Phe	Thr	Glu	Asp	Thr	Glu	Thr	Val	Gly	Gln	Arg
		115					120					125			
Ala	Leu	His	Ser	Ile	Leu	Asn	Ala	Ala	Ile	Met	Ile	Ser	Val	Ile	Val
	130					135					140				
Val	Met	Thr	Ile	Leu	Leu	Val	Val	Leu	Tyr	Lys	Tyr	Arg	Cys	Tyr	Lys
145					150					155					160
Val	Ile	His	Ala	Trp	Leu	Ile	Ile	Ser	Ser	Leu	Leu	Leu	Leu	Phe	Phe
				165					170					175	
Phe	Ser	Phe	Ile	Tyr	Leu	Gly	Glu	Val	Phe	Lys	Thr	Tyr	Asn	Val	Ala
			180					185					190		
Val	Asp	Tyr	Ile	Thr	Val	Ala	Leu	Leu	Ile	Trp	Asn	Phe	Gly	Val	Val
		195					200					205			
Gly	Met	Ile	Ser	Ile	His	Trp	Lys	Gly	Pro	Leu	Arg	Leu	Gln	Gln	Ala
	210					215					220				
Tyr	Leu	Ile	Met	Ile	Ser	Ala	Leu	Met	Ala	Leu	Val	Phe	Ile	Lys	Tyr
225					230					235					240
Leu	Pro	Glu	Trp	Thr	Ala	Trp	Leu	Ile	Leu	Ala	Val	Ile	Ser	Val	Tyr
				245					250					255	

Asp	Leu	Val	Ala	Val	Leu	Cys	Pro	Lys	Gly	Pro	Leu	Arg	Met	Leu	Val
			260					265					270		
Glu	Thr	Ala	Gln	Glu	Arg	Asn	Glu	Thr	Leu	Phe	Pro	Ala	Leu	Ile	Tyr
		275					280					285			
Ser	Ser	Thr	Met	Val	Trp	Leu	Val	Asn	Met	Ala	Glu	Gly	Asp	Pro	Glu
		290				295					300				
Ala	Gln	Arg	Arg	Val	Ser	Lys	Asn	Ser	Lys	Tyr	Asn	Ala	Glu	Ser	Thr
305					310					315					320
Glu	Arg	Glu	Ser	Gln	Asp	Thr	Val	Ala	Glu	Asn	Asp	Asp	Gly	Gly	Phe
				325					330					335	
Ser	Glu	Glu	Trp	Glu	Ala	Gln	Arg	Asp	Ser	His	Leu	Gly	Pro	His	Arg
			340					345					350		
Ser	Thr	Pro	Glu	Ser	Arg	Ala	Ala	Val	Gln	Glu	Leu	Ser	Ser	Ser	Ile
		355					360					365			
Leu	Ala	Gly	Glu	Asp	Pro	Glu	Glu	Arg	Gly	Val	Lys	Leu	Gly	Leu	Gly
		370				375					380				
Asp	Phe	Ile	Phe	Tyr	Ser	Val	Leu	Val	Gly	Lys	Ala	Ser	Ala	Thr	Ala
385					390					395					400
Ser	Gly	Asp	Trp	Asn	Thr	Thr	Ile	Ala	Cys	Phe	Val	Ala	Ile	Leu	Ile
				405					410					415	
Gly	Leu	Cys	Leu	Thr	Leu	Leu	Leu	Leu	Ala	Ile	Phe	Lys	Lys	Ala	Leu
			420					425					430		
Pro	Ala	Leu	Pro	Ile	Ser	Ile	Thr	Phe	Gly	Leu	Val	Phe	Tyr	Phe	Ala
		435					440					445			
Thr	Asp	Tyr	Leu	Val	Gln	Pro	Phe	Met	Asp	Gln	Leu	Ala	Phe	His	Gln
		450				455					460				
Phe	Tyr	Ile													
465															

<210> 2
 <211> 448
 <212> PRT
 <213> human

<400> 2

Met	Leu	Thr	Phe	Met	Ala	Ser	Asp	Ser	Glu	Glu	Glu	Val	Cys	Asp	Glu
1				5					10					15	
Arg	Thr	Ser	Leu	Met	Ser	Ala	Glu	Ser	Pro	Thr	Pro	Arg	Ser	Cys	Gln
			20					25					30		
Glu	Gly	Arg	Gln	Gly	Pro	Glu	Asp	Gly	Glu	Asn	Thr	Ala	Gln	Trp	Arg
		35					40					45			
Ser	Gln	Glu	Asn	Glu	Glu	Asp	Gly	Glu	Glu	Asp	Pro	Asp	Arg	Tyr	Val
		50				55					60				
Cys	Ser	Gly	Val	Pro	Gly	Arg	Pro	Pro	Gly	Leu	Glu	Glu	Glu	Leu	Thr
65					70					75					80
Leu	Lys	Tyr	Gly	Ala	Lys	His	Val	Ile	Met	Leu	Phe	Val	Pro	Val	Thr
				85					90					95	
Leu	Cys	Met	Ile	Val	Val	Val	Ala	Thr	Ile	Lys	Ser	Val	Arg	Phe	Tyr
			100					105					110		
Thr	Glu	Lys	Asn	Gly	Gln	Leu	Ile	Tyr	Thr	Pro	Phe	Thr	Glu	Asp	Thr
		115					120					125			
Pro	Ser	Val	Gly	Gln	Arg	Leu	Leu	Asn	Ser	Val	Leu	Asn	Thr	Leu	Ile
		130				135					140				

Met	Ile	Ser	Val	Ile	Val	Val	Met	Thr	Ile	Phe	Leu	Val	Val	Leu	Tyr
145					150					155					160
Lys	Tyr	Arg	Cys	Tyr	Lys	Phe	Ile	His	Gly	Trp	Leu	Ile	Met	Ser	Ser
			165						170					175	
Leu	Met	Leu	Leu	Phe	Leu	Phe	Thr	Tyr	Ile	Tyr	Leu	Gly	Glu	Val	Leu
			180					185					190		
Lys	Thr	Tyr	Asn	Val	Ala	Met	Asp	Tyr	Pro	Thr	Leu	Leu	Leu	Thr	Val
		195					200					205			
Trp	Asn	Phe	Gly	Ala	Val	Gly	Met	Val	Cys	Ile	His	Trp	Lys	Gly	Pro
	210					215					220				
Leu	Val	Leu	Gln	Gln	Ala	Tyr	Leu	Ile	Met	Ile	Ser	Ala	Leu	Met	Ala
225					230					235					240
Leu	Val	Phe	Ile	Lys	Tyr	Leu	Pro	Glu	Trp	Ser	Ala	Trp	Val	Ile	Leu
				245					250					255	
Gly	Ala	Ile	Ser	Val	Tyr	Asp	Leu	Val	Ala	Val	Leu	Cys	Pro	Lys	Gly
			260					265					270		
Pro	Leu	Arg	Met	Leu	Val	Glu	Thr	Ala	Gln	Glu	Arg	Asn	Glu	Pro	Ile
		275					280					285			
Phe	Pro	Ala	Leu	Ile	Tyr	Ser	Ser	Ala	Met	Val	Trp	Thr	Val	Gly	Met
	290					295					300				
Ala	Lys	Leu	Asp	Pro	Ser	Ser	Gln	Gly	Ala	Leu	Gln	Leu	Pro	Tyr	Asp
305					310					315					320
Pro	Glu	Met	Glu	Glu	Asp	Ser	Tyr	Asp	Ser	Phe	Gly	Glu	Pro	Ser	Tyr
				325					330					335	
Pro	Glu	Val	Phe	Glu	Pro	Pro	Leu	Thr	Gly	Tyr	Pro	Gly	Glu	Glu	Leu
			340					345					350		
Glu	Glu	Glu	Glu	Glu	Arg	Gly	Val	Lys	Leu	Gly	Leu	Gly	Asp	Phe	Ile
		355					360					365			
Phe	Tyr	Ser	Val	Leu	Val	Gly	Lys	Ala	Ala	Ala	Thr	Gly	Ser	Gly	Asp
	370					375					380				
Trp	Asn	Thr	Thr	Leu	Ala	Cys	Phe	Val	Ala	Ile	Leu	Ile	Gly	Leu	Cys
385					390					395					400
Leu	Thr	Leu	Leu	Leu	Ala	Val	Phe	Lys	Lys	Ala	Leu	Pro	Ala	Leu	
				405				410					415		
Pro	Ile	Ser	Ile	Thr	Phe	Gly	Leu	Ile	Phe	Tyr	Phe	Ser	Thr	Asp	Asn
			420					425					430		
Leu	Val	Arg	Pro	Phe	Met	Asp	Thr	Leu	Ala	Ser	His	Gln	Leu	Tyr	Ile
		435					440					445			

<210> 3
 <211> 4746
 <212> DNA
 <213> human

<400> 3

gccagcatcc	cttgtcccgc	ggccgggtca	gacaacaaaa	gcggaagatg	ctgcagttgg	60
gcaaggtcag	gaccttgcc	tgaaagccgg	gcggcgccgc	gcaacgcctc	ttcccggact	120
gaggagctgt	cgccggcgga	gggtgcatgt	ttgcgaggaa	gccgcccggc	gccgcgcctt	180
tgggagctat	gctgtttcca	gaccagcctt	catcagcctc	agagaagacg	agttccctga	240
gccccggctt	aaacacctcc	aacgggggatg	gctctgaaac	agaaaccacc	tctgccatcc	300
tcgcctcagt	caaagaacag	gaattacagt	ttgaaaggct	gacccgagag	ctggaggctg	360
aacggcagat	cgtagccagc	cagctggagc	gatgcaagct	cggatccgag	actggcagca	420
tgagcagcat	gagttcagca	gaagagcagt	ttcagtgcca	gtcacaagat	ggtcaaaaag	480

atatcgaaga	tgagctttaca	acaggtctcg	agctggtgga	ctcctgtatt	aggtcactac	540
aggaatcagg	aatacttgac	ccacaggatt	attctacagg	tgaaaggccc	agcctgctct	600
cccagagtgc	acttcagctc	aattccaaac	ctgaagggtc	tttccagtat	ccggccagct	660
accatagcaa	ccagaccctg	gccctggggg	aaaccacccc	ttcacagctc	ccggcccagag	720
gcacacaagc	ccgagctacg	ggccagagct	tcagccaggg	cacgaccage	cgcgcgggcc	780
acctggcggg	gcccagagccc	gcgcgcgcgc	cgcgcgcgcg	gcccgcggag	ccgttcgcgc	840
ccagcctggg	cagcgcttcc	cacctgcccc	acgcgcgcgc	cgcgcgcgcg	gcccgcgcgc	900
tctactactc	cagctccacg	ctgcccgcgc	cgcgcgcgcg	gggctccccg	ctggccgcgc	960
cccaggggcg	ttcgcccacc	aagctgcagc	gcggcggctc	ggcccccgag	ggcgccacct	1020
acgcgcgcgc	gcgcggctcc	tcgcccgaagc	agtgcgccag	ccgcctggcc	aagtcctaca	1080
gcaccagctc	gcccatacaac	atcgctcgtg	cctcggcggg	cctgtccccg	atccgcgtga	1140
cctcgcccc	caccgtgcag	tccaccatct	cctcctcgcc	catccaccag	ctgagctcca	1200
ccatcggcac	gtacgccacc	ctgtcgccca	ccaagegcct	ggtccacgcg	tccgagcagt	1260
acagcaagca	ctcgaggag	ctgtatgcc	cggccaccct	ccagaggccg	ggcagcctgg	1320
cagctggttc	ccgagcctca	tacagcagcc	agcatgggca	cctggggcca	gagttgcggg	1380
ccctgcagtc	cccagaacac	cacatagatc	ccatctatga	agaccgcgtc	tatcagaagc	1440
cccctatgag	gagtctcagc	cagagccagg	gggacctct	gcccgcagca	cacaccggca	1500
cctaccgcac	gagcacagcc	ccatcttccc	ctggtgtcga	ctccgtcccc	ttgcagcgca	1560
caggcagcca	gcacggccca	cagaatgccg	ccgcggccac	cttccagagg	gccagctatg	1620
ccgcggcccc	agcctccaat	tacgcggacc	cctaccgaca	gctgcagtat	tgtccctctg	1680
ttgagtctcc	atacagcaaa	tccggccctg	ctctcccgcg	tgaaggcacc	ttggccaggt	1740
ccccgtccat	tgatagcatt	cagaaagatc	ccagagaatt	tggatggaga	gacccggaac	1800
gcccgaagt	gattcagatg	ttgcagcacc	agtttccctc	ggtccagtct	aacgcggcag	1860
cttacttgca	acacctctgt	tttgagagaca	acaaaattaa	agccgagata	aggagacaag	1920
gaggcatcca	gctcctgggtg	gacctgttgg	atcatcggat	gaccgaagtc	caccgtagtg	1980
ectgtggagc	tctgagaaac	ctggtgtatg	ggaaggccaa	cgatgataac	aaaattgccc	2040
tgaaaaactg	tgggtggcatc	ccagcactgg	tgaggttact	ccgcaagacg	actgacctgg	2100
agatccggga	gctggtcaca	ggagtccttt	ggaacctctc	ctcatgcgat	gcactcaaaa	2160
tgccaatcat	ccaggatgcc	ctagcagtac	tgaccaacgc	ggtgattatc	ccccactcag	2220
gctgggaaaa	ttcgctctct	caggatgatc	ggaaaataca	gctgcattca	tcacagggtgc	2280
tgcgtaacgc	caccgggtgc	ctaaggaatg	ttagttcggc	cggagaggag	gcccgcagaa	2340
ggatgagaga	gtgtgatggg	cttacggatg	ccttgctgta	cgtgatccag	tctgcgctgg	2400
ggagcagtga	gatcgatagc	aagaccgttg	aaaactgtgt	gtgcatttta	aggaacctct	2460
egtaccggct	ggcggcagaa	acgtctcagg	gacagcacat	gggcacggac	gagctggacg	2520
tgctactctg	tggcgaggcc	aatggcaagg	atgctgagag	ctctgggtgc	tggggcaaga	2580
agaagaagaa	aaagaaatcc	caagatcagt	gggatggagt	aggacctctt	ccagactgtg	2640
ctgaaccacc	aaaagggatc	cagatgctgt	ggcaccctac	aatagtcaaa	ccctacctca	2700
cactgctctc	tgagtgtc	aatccagaca	cgttggaagg	ggcggcaggc	gccctgcaga	2760
acttggctgc	agggagctgg	aagtggctcag	tatatatccg	agccgctgtc	cgaaaagaga	2820
aaggcctgcc	catcctcgtg	gagctgctcc	gaatagacaa	tgaccgtgtg	gtgtgcgcgg	2880
tggccactgc	gctgcggaac	atggccttgg	acgtcagaaa	taaggagctc	atcggcaaat	2940
acgccatgcg	agacctagtc	cacaggcttc	caggagggaa	caacagcaac	aacactgcaa	3000
gcaaggccat	gtcggatgac	acagtgcag	ctgtctgctg	cacactgcac	gaagtgatta	3060
ccaagaacat	ggagaacgcc	aaggccttac	gggatgccgg	tggcatcgag	aagttggctg	3120
gcatctccaa	aagcaaagga	gataaacact	ctccaaaagt	ggtcaaggct	gcatctcagg	3180
tcctcaacag	catgtggcag	taccgagatc	tgaggagtct	ctacaaaaag	gatggatggt	3240
cacaatacca	ctttgtagcc	tcgtcttcaa	ccatcgagag	ggaccggcaa	aggccctact	3300
cctcctcccc	cacgcccctc	atctccccctg	tgcgctgtgc	tcccaacaac	cgctcagcaa	3360
gtgccccagc	ttcacctcgg	gaaatgatca	gcctcaaaga	aaggaaaaca	gactacgagt	3420
gcaccggcag	caacgccacc	taccacggag	ctaaaggcga	acacacttcc	aggaaagatg	3480
ccatgacagc	tcaaaacact	ggaatttcaa	ctttgtatag	gaattcttat	ggtgcgccccg	3540
ctgaagacat	caaacacaac	caggtttcag	cacagccagt	cccacaggag	cccagcagaa	3600
aagattacga	gacctaccag	ccatttcaga	attccacaag	aaattacgat	gagtccttct	3660

tcgaggacca	ggtccaccat	cgccctccc	ccagcgagta	caccatgcac	ctgggtctca	3720
agtccaccgg	caactacgtt	gacttctact	cagctgccc	tccctacagt	gaactgaact	3780
atgaaacgag	ccactaccgg	gcctccccg	actcctgggt	gtgaggagca	gggcacaggc	3840
gctccgggaa	cagtgcattg	gcatgcatac	cacaagacat	ttctttctgt	tttgtttttt	3900
tctcctgcaa	athtagtttg	ttaaagcctg	ttccatagga	aggctgtgat	aaccagtaag	3960
gaaatattaa	gagctatttt	agaaagctaa	atgaatcgca	agttaacttg	gaaatcagta	4020
gaaagctaaa	gtgacccata	atatgacagt	gggcagcacc	tttctagcgt	gagctgtaaa	4080
gtaacgagaa	gtgctttata	ctgaacgtgg	ttgatgggag	gagagacgag	gcattcgggc	4140
cgggtggggcg	taagggttat	cgtaagcac	aagacacaga	atagtattaca	cactgtgtgg	4200
gggacgggctt	ctcacgcttt	gtttactctc	ttcatccgtt	gtgactctag	gcttcagggt	4260
gcattgggggt	tcctctgtac	agcaagatgt	ttcttgccct	ttgttaatgc	attgttgtaa	4320
agtatttgat	gtacattaca	gattaaagaa	gaaaagcgcg	ttgtgtatat	tacaccaatg	4380
ccgccgtgtt	tcctcatcta	tggttctaaa	tattgcttca	atttcaaact	tttgaaagat	4440
gtatggattt	ccagttttttc	tttactttct	cccagtatgt	tttaacaaaa	aaaaaaaaaa	4500
gcaggaaaaa	aggaatattt	agcagtattg	ttcgttctga	tatgtgaatt	tgtttgtgac	4560
aactaaacaa	ggcattcagc	agtttctgac	aattaacata	catcattcca	cactccttgt	4620
caacaaagtg	ctttttcact	gcctaaaatt	ttagatgtag	atatttgaaa	tagatttttt	4680
catttatacc	agttttcttt	atgatgatac	agtgttaaaa	gaaaataaat	tacaattgat	4740
ctgtca						4746

<210> 4
 <211> 1225
 <212> PRT
 <213> human

<400> 4

Met	Phe	Ala	Arg	Lys	Pro	Pro	Gly	Ala	Ala	Pro	Leu	Gly	Ala	Met	Pro
1				5				10						15	
Val	Pro	Asp	Gln	Pro	Ser	Ser	Ala	Ser	Glu	Lys	Thr	Ser	Ser	Leu	Ser
			20					25					30		
Pro	Gly	Leu	Asn	Thr	Ser	Asn	Gly	Asp	Gly	Ser	Glu	Thr	Glu	Thr	Thr
		35					40					45			
Ser	Ala	Ile	Leu	Ala	Ser	Val	Lys	Glu	Gln	Glu	Leu	Gln	Phe	Glu	Arg
	50					55					60				
Leu	Thr	Arg	Glu	Leu	Glu	Ala	Glu	Arg	Gln	Ile	Val	Ala	Ser	Gln	Leu
65					70					75					80
Glu	Arg	Cys	Lys	Leu	Gly	Ser	Glu	Thr	Gly	Ser	Met	Ser	Ser	Met	Ser
				85					90					95	
Ser	Ala	Glu	Glu	Gln	Phe	Gln	Trp	Gln	Ser	Gln	Asp	Gly	Gln	Lys	Asp
			100					105					110		
Ile	Glu	Asp	Glu	Leu	Thr	Thr	Gly	Leu	Glu	Leu	Val	Asp	Ser	Cys	Ile
		115					120					125			
Arg	Ser	Leu	Gln	Glu	Ser	Gly	Ile	Leu	Asp	Pro	Gln	Asp	Tyr	Ser	Thr
						135					140				
Gly	Glu	Arg	Pro	Ser	Leu	Ser	Gln	Ser	Ala	Leu	Gln	Leu	Asn	Ser	
145					150				155					160	
Lys	Pro	Glu	Gly	Ser	Phe	Gln	Tyr	Pro	Ala	Ser	Tyr	His	Ser	Asn	Gln
				165					170					175	
Thr	Leu	Ala	Leu	Gly	Glu	Thr	Thr	Pro	Ser	Gln	Leu	Pro	Ala	Arg	Gly
			180					185					190		
Thr	Gln	Ala	Arg	Ala	Thr	Gly	Gln	Ser	Phe	Ser	Gln	Gly	Thr	Thr	Ser
		195				200						205			
Arg	Ala	Gly	His	Leu	Ala	Gly	Pro	Glu	Pro	Ala	Pro	Pro	Pro	Pro	Pro

210	215	220
Pro Pro Arg Glu Pro Phe Ala Pro Ser Leu Gly Ser Ala Phe His Leu		
225	230	235
Pro Asp Ala Pro Pro Ala Ala Ala Ala Ala Leu Tyr Tyr Ser Ser		240
	245	250
Ser Thr Leu Pro Ala Pro Pro Arg Gly Gly Ser Pro Leu Ala Ala Pro		255
	260	270
Gln Gly Gly Ser Pro Thr Lys Leu Gln Arg Gly Gly Ser Ala Pro Glu		
	275	285
Gly Ala Thr Tyr Ala Ala Pro Arg Gly Ser Ser Pro Lys Gln Ser Pro		
	290	300
Ser Arg Leu Ala Lys Ser Tyr Ser Thr Ser Ser Pro Ile Asn Ile Val		
305	310	315
Val Ser Ser Ala Gly Leu Ser Pro Ile Arg Val Thr Ser Pro Pro Thr		320
	325	330
Val Gln Ser Thr Ile Ser Ser Ser Pro Ile His Gln Leu Ser Ser Thr		335
	340	345
Ile Gly Thr Tyr Ala Thr Leu Ser Pro Thr Lys Arg Leu Val His Ala		350
	355	365
Ser Glu Gln Tyr Ser Lys His Ser Gln Glu Leu Tyr Ala Thr Ala Thr		
	370	380
Leu Gln Arg Pro Gly Ser Leu Ala Ala Gly Ser Arg Ala Ser Tyr Ser		400
385	390	395
Ser Gln His Gly His Leu Gly Pro Glu Leu Arg Ala Leu Gln Ser Pro		415
	405	410
Glu His His Ile Asp Pro Ile Tyr Glu Asp Arg Val Tyr Gln Lys Pro		430
	420	425
Pro Met Arg Ser Leu Ser Gln Ser Gln Gly Asp Pro Leu Pro Pro Ala		445
	435	440
His Thr Gly Thr Tyr Arg Thr Ser Thr Ala Pro Ser Pro Gly Val		460
	450	455
Asp Ser Val Pro Leu Gln Arg Thr Gly Ser Gln His Gly Pro Gln Asn		480
465	470	475
Ala Ala Ala Ala Thr Phe Gln Arg Ala Ser Tyr Ala Ala Gly Pro Ala		495
	485	490
Ser Asn Tyr Ala Asp Pro Tyr Arg Gln Leu Gln Tyr Cys Pro Ser Val		510
	500	505
Glu Ser Pro Tyr Ser Lys Ser Gly Pro Ala Leu Pro Pro Glu Gly Thr		525
	515	520
Leu Ala Arg Ser Pro Ser Ile Asp Ser Ile Gln Lys Asp Pro Arg Glu		540
	530	535
Phe Gly Trp Arg Asp Pro Glu Leu Pro Glu Val Ile Gln Met Leu Gln		560
545	550	555
His Gln Phe Pro Ser Val Gln Ser Asn Ala Ala Tyr Leu Gln His		575
	565	570
Leu Cys Phe Gly Asp Asn Lys Ile Lys Ala Glu Ile Arg Arg Gln Gly		590
	580	585
Gly Ile Gln Leu Leu Val Asp Leu Leu Asp His Arg Met Thr Glu Val		605
	595	600
His Arg Ser Ala Cys Gly Ala Leu Arg Asn Leu Val Tyr Gly Lys Ala		620
	610	615
Asn Asp Asp Asn Lys Ile Ala Leu Lys Asn Cys Gly Gly Ile Pro Ala		640
625	630	635

Leu	Val	Arg	Leu	Leu	Arg	Lys	Thr	Thr	Asp	Leu	Glu	Ile	Arg	Glu	Leu
			645						650					655	
Val	Thr	Gly	Val	Leu	Trp	Asn	Leu	Ser	Ser	Cys	Asp	Ala	Leu	Lys	Met
			660					665					670		
Pro	Ile	Ile	Gln	Asp	Ala	Leu	Ala	Val	Leu	Thr	Asn	Ala	Val	Ile	Ile
		675					680					685			
Pro	His	Ser	Gly	Trp	Glu	Asn	Ser	Pro	Leu	Gln	Asp	Asp	Arg	Lys	Ile
	690					695					700				
Gln	Leu	His	Ser	Ser	Gln	Val	Leu	Arg	Asn	Ala	Thr	Gly	Cys	Leu	Arg
705					710					715					720
Asn	Val	Ser	Ser	Ala	Gly	Glu	Glu	Ala	Arg	Arg	Arg	Met	Arg	Glu	Cys
				725					730					735	
Asp	Gly	Leu	Thr	Asp	Ala	Leu	Leu	Tyr	Val	Ile	Gln	Ser	Ala	Leu	Gly
			740					745					750		
Ser	Ser	Glu	Ile	Asp	Ser	Lys	Thr	Val	Glu	Asn	Cys	Val	Cys	Ile	Leu
		755					760					765			
Arg	Asn	Leu	Ser	Tyr	Arg	Leu	Ala	Ala	Glu	Thr	Ser	Gln	Gly	Gln	His
	770					775					780				
Met	Gly	Thr	Asp	Glu	Leu	Asp	Gly	Leu	Leu	Cys	Gly	Glu	Ala	Asn	Gly
785					790					795					800
Lys	Asp	Ala	Glu	Ser	Ser	Gly	Cys	Trp	Gly	Lys	Lys	Lys	Lys	Lys	Lys
				805					810					815	
Lys	Ser	Gln	Asp	Gln	Trp	Asp	Gly	Val	Gly	Pro	Leu	Pro	Asp	Cys	Ala
			820					825					830		
Glu	Pro	Pro	Lys	Gly	Ile	Gln	Met	Leu	Trp	His	Pro	Ser	Ile	Val	Lys
		835					840					845			
Pro	Tyr	Leu	Thr	Leu	Leu	Ser	Glu	Cys	Ser	Asn	Pro	Asp	Thr	Leu	Glu
	850					855					860				
Gly	Ala	Ala	Gly	Ala	Leu	Gln	Asn	Leu	Ala	Ala	Gly	Ser	Trp	Lys	Trp
865					870					875					880
Ser	Val	Tyr	Ile	Arg	Ala	Ala	Val	Arg	Lys	Glu	Lys	Gly	Leu	Pro	Ile
				885					890					895	
Leu	Val	Glu	Leu	Leu	Arg	Ile	Asp	Asn	Asp	Arg	Val	Val	Cys	Ala	Val
			900					905					910		
Ala	Thr	Ala	Leu	Arg	Asn	Met	Ala	Leu	Asp	Val	Arg	Asn	Lys	Glu	Leu
		915					920					925			
Ile	Gly	Lys	Tyr	Ala	Met	Arg	Asp	Leu	Val	His	Arg	Leu	Pro	Gly	Gly
	930					935					940				
Asn	Asn	Ser	Asn	Asn	Thr	Ala	Ser	Lys	Ala	Met	Ser	Asp	Asp	Thr	Val
945					950					955					960
Thr	Ala	Val	Cys	Cys	Thr	Leu	His	Glu	Val	Ile	Thr	Lys	Asn	Met	Glu
				965					970					975	
Asn	Ala	Lys	Ala	Leu	Arg	Asp	Ala	Gly	Gly	Ile	Glu	Lys	Leu	Val	Gly
			980					985					990		
Ile	Ser	Lys	Ser	Lys	Gly	Asp	Lys	His	Ser	Pro	Lys	Val	Val	Lys	Ala
		995					1000					1005			
Ala	Ser	Gln	Val	Leu	Asn	Ser	Met	Trp	Gln	Tyr	Arg	Asp	Leu	Arg	Ser
	1010					1015					1020				
Leu	Tyr	Lys	Lys	Asp	Gly	Trp	Ser	Gln	Tyr	His	Phe	Val	Ala	Ser	Ser
1025					1030					1035					104
Ser	Thr	Ile	Glu	Arg	Asp	Arg	Gln	Arg	Pro	Tyr	Ser	Ser	Ser	Arg	Thr
				1045					1050					1055	
Pro	Ser	Ile	Ser	Pro	Val	Arg	Val	Ser	Pro	Asn	Asn	Arg	Ser	Ala	Ser

ctgtccccga	tccgcgtgac	ctcgcccccc	accgtgcagt	ccaccatctc	ctcttcgccc	1560
atccaccagc	tgagctccac	catcggcacc	tacgccaccc	tgtcgcgccac	caagcgccctg	1620
gtccacgcgt	ctgagcagta	cagcaagcat	tgcgaggagc	tgtatgccac	cgccaccctc	1680
cagaggccgg	gcagcctggc	agctggatcc	cgagcctcgt	atagcagcca	gcatgggcac	1740
ctggcccttg	agctgcgggc	cctgcagtc	ccagagcacc	acatagaccc	catctatgaa	1800
gaccgtgtct	atcagaagcc	ccctatgagg	agtctcagcc	agagccaggg	ggatcctctg	1860
ccgccagcac	ataccggcac	cttccgcacg	agcacagccc	cgtcctcccc	tgggtgctgac	1920
tccgtccctt	tgcagcgcac	aggcagccaa	cacggggccac	agaatgccgc	cgcagccacc	1980
ttccagaggg	ccagctatgc	tgcgcggccc	gcctccaact	acgcagaccc	ctaccgacag	2040
ctgcagtatt	gtgcctccgt	tgactctccg	tacagcaa	ctggccctgc	cctcccaccc	2100
gaaggcacct	tggccagatc	cccattccatc	gacagcattc	agaaagaccc	cagggagttt	2160
ggatggagag	acccggagct	gcctgaagtg	atacagatgt	tacagcacca	gttcccttca	2220
gtccagtcca	atgctgcagc	ttacctgcaa	cacctctgtt	ttggagacaa	taaaattaag	2280
gcagagataa	ggagacaagg	agggatacag	ctcctggtgg	acctgctgga	tcaccgaatg	2340
acagaagtcc	accgtagtgc	ctgtggggct	ctgaggaacc	tgggtgtatgg	gaaggccaat	2400
gatgataaca	aaatcgccct	gaaaaactgt	ggtggtatcc	cagcgtcgtg	gagactcctt	2460
cgcaagacca	cagacctgga	gatccggggag	ctggtcacag	gagtcctttg	gaacctctca	2520
tcatgtgatg	cactcaaaat	gccaatcatc	caggacgccc	tggcagtgtc	gaccaatgcg	2580
gtgattatcc	ctcactcggg	ctgggagaat	tcacctcttc	aggatgatcg	gaaaatacag	2640
ctgcattcat	cacaggtgct	gcgcaacgcc	actgggtgcc	taaggaatgt	aagttcagct	2700
ggagaggagg	cccgccgaag	gatgcggggag	tgtgatgggc	tcacggatgc	cttgctgtac	2760
gtgatccagt	ctgcaactgg	gagcagtgcg	atcgatagca	agaccgttga	aaactgtgtg	2820
ctgcatcttga	ggaacctctc	ctaccggcta	gcagcagaaa	cgtctcaggg	acagcacatg	2880
ctggcacagacg	agctggacgg	gctgctctgc	ggggagacca	acggcaaaga	cacagagagt	2940
ctggtgtgct	ggggcaagaa	gaagaagaaa	aagaaatccc	aggaccagtg	ggatggagta	3000
ggacctcttc	cagactgtgc	agagccacca	aaagggatcc	agatgctgtg	gcaccctgcc	3060
atagtcaaac	cctacctcac	actgctctct	gagtgtctca	acccagacac	gctggaaggg	3120
gcagcggggcg	ccctgcagaa	cttggtctgca	gggagctgga	agggctgggc	tgaggatgtg	3180
gcaggcatgg	cgtatgccct	acgttcaactg	ccagaggggg	ctccctgcct	gccacagtgg	3240
cccggtgata	tccgagctgc	tgtccggaaa	gagaaaggcc	tgccattctc	tgtggagctc	3300
ctccgaatag	acaatgaccg	tgtagtgtgt	gcagtggcca	cagcacttcg	gaacatggcc	3360
ctcgaatgtca	gaaacaagga	actcattggc	aagtatgcca	tgcgagacct	ggtccaccgg	3420
cttccctggtg	ggaacaacag	caacaactcg	gggagcaagg	ccatgtcaga	tgacaccgtg	3480
acggcccggtg	gctgcacctt	gcataagagt	atcaccaaga	acatggagaa	tgccaaggcc	3540
cttacgggatg	ctggtggcat	cgagaagtgt	gtcggcatct	ctaaaagcaa	aggagacaag	3600
cactctccaa	aggtggtcaa	ggctgcttct	caggtcctaa	acagcatgtg	gcagtatcgc	3660
gatctgagga	gtctctacaa	gaaggatgga	tggtcacaa	atcactttgt	agcctcatct	3720
tcaaccatcg	agagggatcg	acaaaggccc	tactcctcct	cccgcacacc	ctccatctct	3780
cccgtgcgtg	tgtctcccaa	caaccgctca	gcaagtgcct	cagcttcacc	tcgggaaatg	3840
atcagcctca	aagaaaggaa	gacggactac	gagtccgctg	gcaacaacgc	cacttaccac	3900
ggaactaaag	gagaacacac	ctccagaaaa	gacaccatga	cagctcaaaa	cactggagtt	3960
tcaactttgt	acaggaattc	atacgggtgc	cccgctgaag	acatcaaaca	gaaccaggtt	4020
tccacacagc	ctgtccctca	ggagcccagc	aggaaagact	acgagaccta	ccagcccttt	4080
ccgaattcca	cacgaaatta	tgatgagtc	ttctttgagg	accaggtcca	ccaccgccct	4140
ccagccagcg	agtacaccat	gcacctgggc	ctcaagtcca	ctggcaacta	tgtcgacttc	4200
tactctgcag	cccgctcctta	cagtgaactg	aactatgaaa	cgagccacta	cccgccctcg	4260
cccgactcct	gggtgtaagg	agccaggaca	cgaggcactc	cggggacagt	gcatgtgcat	4320
gcatacacca	caggacattt	tgtttctttt	tttcttttct	tttcttttgt	tttttttttt	4380
ttttctttcc	ctgcaaatct	agtttggttaa	agcctgttcc	gtaggaaggc	tgtgataacc	4440
aggaagaaat	actcagagct	attttagaaa	gctaaaatga	atcaagagtt	aactgggaaa	4500
tcgataggaa	gctaaacgca	atcctaattg	tgaccgcatt	caacaccttt	ctagtttgaa	4560
ctatagcatt	ttgaaagtgc	tttatagtcc	ggtgaggctg	aaggtaggag	agaggagaca	4620
gtcagggtgg	tgggcgtggg	tatcgctaag	cacaagacag	actagtttac	acactgtggg	4680

gacgggttct	cacgctttgt	ttactctctt	catccgtgtg	actctaggct	tcaagttgca	4740
ttgggggtcc	tctgtacagc	aagacgtctc	ttgccttttg	ttaatgcatt	gttgtaaagt	4800
attcgatgta	cattacagat	taaagacgaa	gagtgcatgg	tgtatattac	accaatgcca	4860
ctgtgtttcc	tcatcaatgg	ttctaaatat	tgcttcaatt	tcaaactttt	gaaagatgta	4920
tgggtttcca	atcttctttt	tttttttctt	tctcccagta	tgttttaaca	aaaaaggaaa	4980
aaaaaaacag	gaaaaaaa					4998

<210> 6
 <211> 1247
 <212> PRT
 <213> mouse

<400> 6

Met	Phe	Ala	Arg	Lys	Gln	Ser	Gly	Ala	Ala	Pro	Phe	Gly	Ala	Met	Pro
1				5					10					15	
Val	Pro	Asp	Gln	Pro	Pro	Ser	Ala	Ser	Glu	Lys	Asn	Ser	Ser	Leu	Ser
			20					25					30		
Pro	Gly	Leu	Asn	Thr	Ser	Asn	Gly	Asp	Gly	Ser	Glu	Thr	Glu	Thr	Thr
		35					40					45			
Ser	Ala	Ile	Leu	Ala	Ser	Val	Lys	Glu	Gln	Glu	Leu	Gln	Phe	Glu	Arg
	50					55					60				
Leu	Thr	Arg	Glu	Leu	Glu	Ala	Glu	Arg	Gln	Ile	Val	Ala	Ser	Gln	Leu
65				70					75					80	
Glu	Arg	Cys	Lys	Leu	Gly	Ser	Glu	Thr	Gly	Ser	Met	Ser	Ser	Ile	Ser
			85						90					95	
Ser	Ala	Gly	Glu	Gln	Phe	His	Trp	Gln	Thr	Gln	Asp	Gly	Gln	Lys	Asp
			100					105					110		
Ile	Glu	Asp	Glu	Leu	Thr	Thr	Gly	Leu	Glu	Leu	Val	Asp	Ser	Cys	Ile
	115						120					125			
Arg	Ser	Leu	Gln	Glu	Ser	Gly	Ile	Leu	Asp	Pro	Gln	Asp	Tyr	Ser	Thr
	130					135					140				
Ser	Glu	Arg	Pro	Ser	Leu	Leu	Ser	Gln	Ser	Ala	Leu	Gln	Leu	Asn	Ser
145				150						155				160	
Lys	Pro	Glu	Gly	Ser	Phe	Gln	Tyr	Pro	Ala	Ser	Tyr	His	Ser	Asn	Gln
			165						170					175	
Thr	Leu	Ala	Leu	Gly	Asp	Thr	Ala	Pro	Ser	Gln	Leu	Pro	Ala	Arg	Ser
			180					185					190		
Thr	Gln	Ala	Arg	Ala	Ala	Gly	Gln	Ser	Phe	Ser	Gln	Gly	Thr	Thr	Gly
	195					200						205			
Arg	Ala	Gly	His	Leu	Ala	Gly	Ser	Glu	Pro	Ala	Pro	Pro	Pro	Pro	Pro
	210					215					220				
Pro	Arg	Glu	Pro	Phe	Ala	Pro	Ser	Leu	Gly	Ser	Ala	Phe	His	Leu	Pro
225				230						235				240	
Asp	Ala	Pro	Pro	Ala	Ala	Ala	Leu	Tyr	Tyr	Ser	Ser	Ser	Ser	Thr	Leu
			245					250						255	
Pro	Ala	Pro	Pro	Arg	Gly	Gly	Ser	Pro	Leu	Thr	Thr	Thr	Gln	Gly	Gly
			260					265					270		
Ser	Pro	Thr	Lys	Leu	Gln	Arg	Gly	Gly	Ser	Ala	Pro	Glu	Gly	Ala	Ala
		275					280					285			
Tyr	Ala	Ala	Pro	Arg	Gly	Ser	Ser	Pro	Lys	Gln	Ser	Pro	Ser	Arg	Leu
	290					295					300				
Ala	Lys	Ser	Tyr	Ser	Thr	Ser	Ser	Pro	Ile	Asn	Ile	Val	Val	Ser	Ser
305					310					315					320

Ala	Gly	Leu	Ser	Pro	Ile	Arg	Val	Thr	Ser	Pro	Pro	Thr	Val	Gln	Ser
				325					330					335	
Thr	Ile	Ser	Ser	Ser	Pro	Ile	His	Gln	Leu	Ser	Ser	Thr	Ile	Gly	Thr
				340				345					350		
Tyr	Ala	Thr	Leu	Ser	Pro	Thr	Lys	Arg	Leu	Val	His	Ala	Ser	Glu	Gln
				355				360				365			
Tyr	Ser	Lys	His	Ser	Gln	Glu	Leu	Tyr	Ala	Thr	Ala	Thr	Leu	Gln	Arg
				370				375			380				
Pro	Gly	Ser	Leu	Ala	Ala	Gly	Ser	Arg	Ala	Ser	Tyr	Ser	Ser	Gln	His
385					390					395					400
Gly	His	Leu	Ala	Pro	Glu	Leu	Arg	Ala	Leu	Gln	Ser	Pro	Glu	His	His
				405					410					415	
Ile	Asp	Pro	Ile	Tyr	Glu	Asp	Arg	Val	Tyr	Gln	Lys	Pro	Pro	Met	Arg
				420				425					430		
Ser	Leu	Ser	Gln	Ser	Gln	Gly	Asp	Pro	Leu	Pro	Pro	Ala	His	Thr	Gly
				435				440				445			
Thr	Phe	Arg	Thr	Ser	Thr	Ala	Pro	Ser	Ser	Pro	Gly	Val	Asp	Ser	Val
						455					460				
Pro	Leu	Gln	Arg	Thr	Gly	Ser	Gln	His	Gly	Pro	Gln	Asn	Ala	Ala	Ala
465					470					475					480
Ala	Thr	Phe	Gln	Arg	Ala	Ser	Tyr	Ala	Ala	Gly	Pro	Ala	Ser	Asn	Tyr
				485					490					495	
Ala	Asp	Pro	Tyr	Arg	Gln	Leu	Gln	Tyr	Cys	Ala	Ser	Val	Asp	Ser	Pro
				500				505					510		
Tyr	Ser	Lys	Ser	Gly	Pro	Ala	Leu	Pro	Pro	Glu	Gly	Thr	Leu	Ala	Arg
				515				520				525			
Ser	Pro	Ser	Ile	Asp	Ser	Ile	Gln	Lys	Asp	Pro	Arg	Glu	Phe	Gly	Trp
				530				535				540			
Arg	Asp	Pro	Glu	Leu	Pro	Glu	Val	Ile	Gln	Met	Leu	Gln	His	Gln	Phe
545					550					555					560
Pro	Ser	Val	Gln	Ser	Asn	Ala	Ala	Ala	Tyr	Leu	Gln	His	Leu	Cys	Phe
				565					570					575	
Gly	Asp	Asn	Lys	Ile	Lys	Ala	Glu	Ile	Arg	Arg	Gln	Gly	Gly	Ile	Gln
				580				585					590		
Leu	Leu	Val	Asp	Leu	Leu	Asp	His	Arg	Met	Thr	Glu	Val	His	Arg	Ser
				595			600					605			
Ala	Cys	Gly	Ala	Leu	Arg	Asn	Leu	Val	Tyr	Gly	Lys	Ala	Asn	Asp	Asp
				610			615				620				
Asn	Lys	Ile	Ala	Leu	Lys	Asn	Cys	Gly	Gly	Ile	Pro	Ala	Leu	Val	Arg
625					630					635					640
Leu	Leu	Arg	Lys	Thr	Asp	Leu	Glu	Ile	Arg	Glu	Leu	Val	Thr	Gly	
				645				650					655		
Val	Leu	Trp	Asn	Leu	Ser	Ser	Cys	Asp	Ala	Leu	Lys	Met	Pro	Ile	Ile
				660				665					670		
Gln	Asp	Ala	Leu	Ala	Val	Leu	Thr	Asn	Ala	Val	Ile	Ile	Pro	His	Ser
				675				680				685			
Gly	Trp	Glu	Asn	Ser	Pro	Leu	Gln	Asp	Asp	Arg	Lys	Ile	Gln	Leu	His
				690			695				700				
Ser	Ser	Gln	Val	Leu	Arg	Asn	Ala	Thr	Gly	Cys	Leu	Arg	Asn	Val	Ser
705					710					715					720
Ser	Ala	Gly	Glu	Glu	Ala	Arg	Arg	Arg	Met	Arg	Glu	Cys	Asp	Gly	Leu
				725					730					735	
Thr	Asp	Ala	Leu	Leu	Tyr	Val	Ile	Gln	Ser	Ala	Leu	Gly	Ser	Ser	Glu

			740					745				750			
Ile	Asp	Ser	Lys	Thr	Val	Glu	Asn	Cys	Val	Cys	Ile	Leu	Arg	Asn	Leu
		755					760					765			
Ser	Tyr	Arg	Leu	Ala	Ala	Glu	Thr	Ser	Gln	Gly	Gln	His	Met	Gly	Thr
	770					775					780				
Asp	Glu	Leu	Asp	Gly	Leu	Leu	Cys	Gly	Glu	Thr	Asn	Gly	Lys	Asp	Thr
785					790				795						800
Glu	Ser	Ser	Gly	Cys	Trp	Gly	Lys	Lys	Lys	Lys	Lys	Lys	Lys	Ser	Gln
			805					810							815
Asp	Gln	Trp	Asp	Gly	Val	Gly	Pro	Leu	Pro	Asp	Cys	Ala	Glu	Pro	Pro
		820						825					830		
Lys	Gly	Ile	Gln	Met	Leu	Trp	His	Pro	Ser	Ile	Val	Lys	Pro	Tyr	Leu
	835						840					845			
Thr	Leu	Leu	Ser	Glu	Cys	Ser	Asn	Pro	Asp	Thr	Leu	Glu	Gly	Ala	Ala
	850					855					860				
Gly	Ala	Leu	Gln	Asn	Leu	Ala	Ala	Gly	Ser	Trp	Lys	Gly	Trp	Ala	Glu
865					870				875						880
Asp	Val	Ala	Gly	Met	Ala	Tyr	Ala	Leu	Arg	Ser	Leu	Pro	Glu	Gly	Ala
			885						890						895
Pro	Cys	Leu	Pro	Gln	Trp	Ser	Val	Tyr	Ile	Arg	Ala	Ala	Val	Arg	Lys
		900						905					910		
Glu	Lys	Gly	Leu	Pro	Ile	Leu	Val	Glu	Leu	Leu	Arg	Ile	Asp	Asn	Asp
	915						920					925			
Arg	Val	Val	Cys	Ala	Val	Ala	Thr	Ala	Leu	Arg	Asn	Met	Ala	Leu	Asp
	930					935					940				
Val	Arg	Asn	Lys	Glu	Leu	Ile	Gly	Lys	Tyr	Ala	Met	Arg	Asp	Leu	Val
945					950				955						960
His	Arg	Leu	Pro	Gly	Gly	Asn	Asn	Ser	Asn	Asn	Ser	Gly	Ser	Lys	Ala
			965						970					975	
Met	Ser	Asp	Asp	Thr	Val	Thr	Ala	Val	Cys	Cys	Thr	Leu	His	Glu	Val
		980						985					990		
Ile	Thr	Lys	Asn	Met	Glu	Asn	Ala	Lys	Ala	Leu	Arg	Asp	Ala	Gly	Gly
	995						1000					1005			
Ile	Glu	Lys	Leu	Val	Gly	Ile	Ser	Lys	Ser	Lys	Gly	Asp	Lys	His	Ser
	1010					1015					1020				
Pro	Lys	Val	Val	Lys	Ala	Ala	Ser	Gln	Val	Leu	Asn	Ser	Met	Trp	Gln
1025					1030					1035					104
Tyr	Arg	Asp	Leu	Arg	Ser	Leu	Tyr	Lys	Lys	Asp	Gly	Trp	Ser	Gln	Tyr
			1045						1050					1055	
His	Phe	Val	Ala	Ser	Ser	Ser	Thr	Ile	Glu	Arg	Asp	Arg	Gln	Arg	Pro
		1060						1065					1070		
Tyr	Ser	Ser	Ser	Arg	Thr	Pro	Ser	Ile	Ser	Pro	Val	Arg	Val	Ser	Pro
	1075						1080					1085			
Asn	Asn	Arg	Ser	Ala	Ser	Ala	Pro	Ala	Ser	Pro	Arg	Glu	Met	Ile	Ser
	1090					1095					1100				
Leu	Lys	Glu	Arg	Lys	Thr	Asp	Tyr	Glu	Ser	Ala	Gly	Asn	Asn	Ala	Thr
1105					1110					1115					112
Tyr	His	Gly	Thr	Lys	Gly	Glu	His	Thr	Ser	Arg	Lys	Asp	Thr	Met	Thr
			1125						1130					1135	
Ala	Gln	Asn	Thr	Gly	Val	Ser	Thr	Leu	Tyr	Arg	Asn	Ser	Tyr	Gly	Ala
		1140						1145					1150		
Pro	Ala	Glu	Asp	Ile	Lys	Gln	Asn	Gln	Val	Ser	Thr	Gln	Pro	Val	Pro
	1155						1160					1165			

